Oryzon Genomics — Capital raise to support long-term strategy
Oryzon has secured €30m through an equity raise (straight equity, no warrants attached) to support clinical development activities and other...
265 Views
Oryzon Genomics — First patient dosed in iadademstat + ICI SCLC trial
Oryzon Genomics has announced that the first patient has been dosed in iadademstat’s Phase I/II trial, sponsored by the National Cancer Institute,...
268 Views
Oryzon Genomics — All steady heading into 2025
Oryzon has reported its FY24 results, reflecting steady progress across its pipeline. Oryzon’s highest value-driving programme remains vafidemstat...
164 Views
Oryzon Genomics - Q3 results recap key upcoming inflection points
Oryzon has reported its Q324 results, the highlight of which was the borderline personality disorder (BPD) programme, with the final Phase IIb...
288 Views
Oryzon Genomics - FDA aligns on Phase III BPD plans
Oryzon Genomics has confirmed the FDA’s alignment with its proposed Phase III programme for vafidemstat in borderline personality disorder (BPD)....
359 Views